GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more
GeneReach Biotechnology (4171) - Net Assets
Latest net assets as of September 2025: NT$591.73 Million TWD
Based on the latest financial reports, GeneReach Biotechnology (4171) has net assets worth NT$591.73 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$877.51 Million) and total liabilities (NT$285.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$591.73 Million |
| % of Total Assets | 67.43% |
| Annual Growth Rate | 16.4% |
| 5-Year Change | -15.42% |
| 10-Year Change | N/A |
| Growth Volatility | 35.9 |
GeneReach Biotechnology - Net Assets Trend (2017–2024)
This chart illustrates how GeneReach Biotechnology's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GeneReach Biotechnology (2017–2024)
The table below shows the annual net assets of GeneReach Biotechnology from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$725.49 Million | -15.88% |
| 2023-12-31 | NT$862.44 Million | -21.79% |
| 2022-12-31 | NT$1.10 Billion | +1.34% |
| 2021-12-31 | NT$1.09 Billion | +26.85% |
| 2020-12-31 | NT$857.76 Million | +44.64% |
| 2019-12-31 | NT$593.05 Million | +90.60% |
| 2018-12-31 | NT$311.15 Million | +24.15% |
| 2017-12-31 | NT$250.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to GeneReach Biotechnology's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14598500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$798.15 Million | 111.32% |
| Total Equity | NT$716.98 Million | 100.00% |
GeneReach Biotechnology Competitors by Market Cap
The table below lists competitors of GeneReach Biotechnology ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Emperor International Holdings Limited
F:EM3A
|
$24.07 Million |
|
Dolphin Offshore Enterprises (India) Limited
NSE:DOLPHIN
|
$24.07 Million |
|
Marvipol S.A.
WAR:MVP
|
$24.07 Million |
|
SJ Group Co. Ltd
KQ:306040
|
$24.08 Million |
|
Ozerden Plastik Sanayi
IS:OZRDN
|
$24.04 Million |
|
Palisades Goldcorp Ltd.
PINK:PLGDF
|
$24.03 Million |
|
Getchell Gold Corp
OTCQB:GGLDF
|
$24.03 Million |
|
Menon Bearings Limited
NSE:MENONBE
|
$24.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneReach Biotechnology's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 832,062,000 to 716,980,000, a change of -115,082,000 (-13.8%).
- Net loss of 118,734,000 reduced equity.
- Dividend payments of 15,991,000 reduced retained earnings.
- Other factors increased equity by 19,643,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-118.73 Million | -16.56% |
| Dividends Paid | NT$15.99 Million | -2.23% |
| Other Changes | NT$19.64 Million | +2.74% |
| Total Change | NT$- | -13.83% |
Book Value vs Market Value Analysis
This analysis compares GeneReach Biotechnology's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.52x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.68x to 1.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$7.09 | NT$19.00 | x |
| 2018-12-31 | NT$8.10 | NT$19.00 | x |
| 2019-12-31 | NT$13.29 | NT$19.00 | x |
| 2020-12-31 | NT$14.13 | NT$19.00 | x |
| 2021-12-31 | NT$17.91 | NT$19.00 | x |
| 2022-12-31 | NT$18.01 | NT$19.00 | x |
| 2023-12-31 | NT$14.48 | NT$19.00 | x |
| 2024-12-31 | NT$12.48 | NT$19.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneReach Biotechnology utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -57.50%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.49x
- Recent ROE (-16.56%) is below the historical average (7.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -19.20% | -30.97% | 0.26x | 2.41x | NT$-73.19 Million |
| 2018 | 9.89% | 15.24% | 0.27x | 2.40x | NT$-313.60K |
| 2019 | 13.89% | 21.10% | 0.48x | 1.37x | NT$21.63 Million |
| 2020 | 31.65% | 30.02% | 0.69x | 1.53x | NT$175.98 Million |
| 2021 | 35.88% | 37.21% | 0.60x | 1.60x | NT$271.64 Million |
| 2022 | 20.73% | 29.51% | 0.46x | 1.52x | NT$114.57 Million |
| 2023 | -19.98% | -73.75% | 0.19x | 1.41x | NT$-249.48 Million |
| 2024 | -16.56% | -57.50% | 0.19x | 1.49x | NT$-190.43 Million |
Industry Comparison
This section compares GeneReach Biotechnology's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneReach Biotechnology (4171) | NT$591.73 Million | -19.20% | 0.48x | $24.05 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |